I型干扰素自身抗体阳性与COVID-19疫苗不良反应之间无关联。
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.
作者信息
Yalcinkaya Ahmet, Cavalli Marco, Cederholm Axel, Aranda-Guillén Maribel, Behere Anish, Mildner Hedvig, Lakshmikanth Tadepally, Gonzalez Laura, Mugabo Constantin Habimana, Johnsson Anette, Ekwall Olov, Kämpe Olle, Bensing Sophie, Brodin Petter, Hallberg Pär, Wadelius Mia, Landegren Nils
机构信息
Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Department of Medical Biochemistry, Hacettepe University Hospital, Ankara, Turkey.
出版信息
NPJ Vaccines. 2024 Feb 22;9(1):42. doi: 10.1038/s41541-024-00829-9.
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
I型干扰素作为抵御病毒感染的守门人，而中和这些信号分子的自身抗体已被证明与COVID-19的严重程度以及对减毒活黄热病疫苗的不良反应有关。在此背景下，我们试图研究针对I型干扰素的自身抗体是否与COVID-19疫苗接种后的不良事件相关。我们的全国性分析表明，I型干扰素自身抗体与mRNA或病毒载体COVID-19疫苗接种后的不良事件无关。
Zotero 插件